10-Q · May 13, 2026
OptimizeRx reported a Q1 2026 revenue of $19.8 million, showing a 10% decline year-over-year but exceeding consensus estimates. The company achieved an EPS of $0.14, significantly ahead of the expected loss of $0.02,…
Earnings analysis · 10-Q
OPRX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
OptimizeRx reported Q2 revenue of $20.504 million and non-GAAP diluted EPS of $0.16, exceeding consensus estimates, but GAAP diluted EPS was $(0.04). The 10-Q highlights continued remediation of a material weakness,…
Read full summary
OptimizeRx reported Q2 revenue of $20.504 million and non-GAAP diluted EPS of $0.16, exceeding consensus estimates, but GAAP diluted EPS was $(0.04). The 10-Q highlights continued remediation of a material weakness, with 3 of 4 third-party service organizations remediated and 1 remaining. No material risk-factor changes were disclosed versus the 2025 10-K, but ineffective disclosure controls and the remaining third-party data weakness are material concerns.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.04
What stood out
-
Revenue Beat Estimates
Q2 revenue was $20.504 million, modestly above the $20.2592 million consensus estimate by approximately 1.2%.
-
Adjusted EPS Beat, GAAP Loss
Non-GAAP diluted EPS was $0.16 versus the $0.09 estimate, a $0.07 beat; however, GAAP diluted EPS was $(0.04).
-
Control Remediation Progress
Management stated that it remediated the material weakness for 3 of 4 third-party service organizations during 2025, leaving 1 organization in the process of full remediation.
-
No Material Legal Proceedings
The company reported no material legal or administrative proceedings and no pending or threatened material proceedings.
What to watch
-
Material Weakness Remains
Disclosure controls and procedures were not effective as of June 30, 2026 because of a material weakness involving controls over the completeness and accuracy of data received from 1 remaining third-party service organization.
-
Third-Party Data Control Risk
The company relies on SOC-1 Type 2 reports from each third-party service organization; if such a report or substantive testing is unavailable, it may need to modify contracts, limit activity, or add operational controls.
-
GAAP Profitability Gap
GAAP diluted EPS was $(0.04), despite non-GAAP diluted EPS of $0.16, indicating a $0.20 difference between GAAP and adjusted earnings measures.
Management's outlook
The 10-Q does not provide explicit quantitative guidance. Fiscal 2026 revenue guidance of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million were reaffirmed in the August 12, 2026 earnings release, not in the extracted 10-Q text.
Earlier filings 4
10-K · March 12, 2026
OptimizeRx’s 2025 10‑K describes a strategic shift toward subscriptionable, AI-enabled DAAP and MNT offerings and an explicit goal to be a “Rule of 40” company within the next several years. Financially, the company…
10-Q · November 7, 2025
OptimizeRx reported a strong quarter: net revenue rose 22% year-over-year to $26,067 for Q3 2025, gross margin expanded to 67.2% and the company returned to profitability with net income of $779 (three months ended…
10-Q · August 8, 2025
OptimizeRx reported a strong quarter ended June 30, 2025 with net revenue up 55% year-over-year to $29,195,000 and a return to profitability with net income of $1,532,000 for the quarter. Gross margin expanded to 63.8%…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.